Clinical Cancer Research, 16(7), 2187-2197. American Association for Cancer Research Inc. Langenberg, M H G, Witteveen, P O, Roodhart, J M, Verheul, H M W, Mergui-Roelvink, M, van der Sar, J, Brendel, E, Laferriere, N, Schellens, J H M & Voest, E E 2010, ' Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors ', Clinical Cancer Research, vol. 16, no. 7, pp. 2187-2197 . https://doi.org/10.1158/1078-0432.CCR-09-2436